Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$19.25 ▼ -0.43
(-2.18%)
MKT CAP: $1.16B • VOL: 624.1K
52W L $7 52W H $26
ROARABLE / RQD
D- • 42/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$16
MEDIAN
$22
MEAN
$22
HIGH
$26
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VOR TAPE
VOR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $23.29 | $22.14 | 2025-02-14 | $17.52 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $24.25 | $22.71 | 2025-02-06 | $18.09 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $21.94 | $21.18 | 2025-01-29 | $18.48 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $19.64 | — | 2025-01-17 | $18.86 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $16.94 | $18.29 | 2025-01-09 | $17.13 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $22.91 | $20.02 | 2024-12-18 | $16.75 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $18.67 | $19.44 | 2024-12-04 | $17.90 | -4.3% | 48% | C |